Clinical Trial Detail

NCT ID NCT03395197
Title Talazoparib + NHT vs. NHT Monotherapy in DDR+ mCRPC (TALAPRO-2)
Recruitment Recruiting
Gender male
Phase Phase III
Variant Requirements no
Sponsors Pfizer
Indications

prostate adenocarcinoma

Therapies

Talazoparib

Age Groups: adult senior

No variant requirements are available.